<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823510</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 13-0208</org_study_id>
    <nct_id>NCT01823510</nct_id>
  </id_info>
  <brief_title>Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients</brief_title>
  <official_title>Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan J Badimon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more
      effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes. Both
      treatments will be given (separately) to all subjects as a one-time loading dose (i.e. higher
      than a normal daily dose), followed by daily dose for the next 5 to 7 days. Effectiveness of
      treatment will be measured with specialized blood tests before the loading dose, at two
      time-points after the loading dose, and once after the last daily dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rising prevalence of diabetes mellitus and its associated cardiovascular complications
      present a major burden to healthcare providers worldwide. Cardiovascular mortality is much
      higher among subjects with Type 2 Diabetes Mellitus (T2DM). Increased platelet reactivity is
      considered a potential link between the two diseases. Thus, given the higher blood
      thrombogenicity of T2DM with CAD, the availability of more potent antiplatelet drugs should
      be associated with improvements in the prevention of cardiovascular events in the diabetic
      populations. Ticagrelor has been shown to possess a faster onset of action and more potency
      than clopidogrel. Furthermore, the PLATO has shown that these characteristics results in a
      significant reduction in Cardiovascular events and even death as compared with Clopidogrel.

      We plan to compare the antithrombotic activity of ticagrelor versus clopidogrel in T2DM
      patients using a cross-over study design. Each participant will be randomly assigned to
      receive ticagrelor/clopidogrel + aspirin as a loading dose followed by 5-7 days of daily
      maintenance dosing. After a washout period of 1-2 weeks, each participant will receive the
      second treatment (clopidogrel/ticagrelor + aspirin) again as a loading dose followed by 5-7
      days of daily dosing. Platelet function will be tested at pre-treatment baseline, two
      post-dose time-points on the day of loading dose, and one time-point after the last
      maintenance dose on day 5-7. Platelet testing will be carried out using the following
      methodologies:

        1. Badimon Perfusion Chamber: an ex-vivo model of thrombosis that has been extensively
           utilized for evaluation of antithrombotic or prothrombotic effects under various
           pathological states. The model involves native blood perfusing over a thrombogenic
           substrate, triggering thrombus formation that can be measured by planimetry.

        2. Platelet Aggregation - Multiplate Analyzer.

        3. Platelet Aggregation - VerifyNow P2Y12 assay.

        4. Vasodilator-Stimulated Phosphoprotein (VASP).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">May 10, 2016</completion_date>
  <primary_completion_date type="Actual">May 10, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombus Formation</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Thrombus formation in Badimon Perfusion Chamber high-shear) (ex vivo model of thrombosis).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Platelet reactivity by Multiplate Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>P2Y12 Reaction Unit (PRU)</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Platelet reactivity by measuring P2Y12 Reaction Unit using Accumetrics VerifyNow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Index (PRI)</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Platelet reactivity index by Vasodilator-Stimulated Phosphoprotein phosphorylation (VASP) assay.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type-2 Diabetes Mellitus</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor + Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loading-dose plus daily-dosing for 5-7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel + Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loading-dose plus daily-dosing for 5-7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor + Aspirin</intervention_name>
    <description>Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).</description>
    <arm_group_label>Ticagrelor + Aspirin</arm_group_label>
    <other_name>Brilinta (ticagrelor)</other_name>
    <other_name>Aspirin (ASA)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel + Aspirin</intervention_name>
    <description>Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).</description>
    <arm_group_label>Clopidogrel + Aspirin</arm_group_label>
    <other_name>Plavix (clopidogrel)</other_name>
    <other_name>Aspirin (ASA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with type-2 diabetes being treated with oral or parenteral hypoglycemic
             therapy or both.

          -  Have not had thienopyridine therapy for at least 30 days before the study.

          -  Are of legal age (at least 18 years of age but less than 75 years of age) and
             competent mental condition to provide written informed consent.

          -  For women of child-bearing potential only test negative for pregnancy at the time of
             enrollment.

        Exclusion Criteria:

          -  Have a defined need for thienopyridine therapy.

          -  Subjects within ≤30 days of coronary artery bypass graft (CABG) surgery or
             percutaneous coronary intervention (PCI).

          -  Known glycosylated hemoglobin (HbA1c) ≥10 mg/dL within last 3 months prior to study
             entry.

          -  Have received fibrinolytic therapy &lt;48 hours prior to randomization.

          -  Have active internal bleeding or history of bleeding diathesis.

          -  Have clinical findings that are, in the judgment of the investigator, associated with
             an increased risk of bleeding.

          -  Have history of ischemic or hemorrhagic stroke, transient ischemic attack (TIA) or
             intracranial neoplasm, arteriovenous malformation, or aneurysm.

          -  Have an International Normalized Ratio (INR) known to be &gt;1.5 within 1 week of study
             entry.

          -  Have a known platelet count of &lt;100,000/mm3 within 1 week of study entry.

          -  Have known anemia (hemoglobin [Hgb] &lt;10 gm/dL) within 1 week of study entry.

          -  Are receiving or will receive oral anticoagulation or other antiplatelet therapy
             (other than ASA) that cannot be safely discontinued for the duration of the trial.

          -  Are receiving daily treatment with non-steroidal anti-inflammatory drugs (NSAIDS) that
             cannot be discontinued.

          -  Have a concomitant medical illness that in the opinion of the investigator may
             interfere with or prevent completion in this study.

          -  Have known severe hepatic dysfunction (e.g., cirrhosis or portal hypertension).

          -  Have a history of intolerance or allergy to ASA or approved thienopyridines
             (ticlopidine or clopidogrel).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan J Badimon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2013</study_first_submitted>
  <study_first_submitted_qc>March 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2013</study_first_posted>
  <results_first_submitted>June 19, 2017</results_first_submitted>
  <results_first_submitted_qc>August 2, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 1, 2017</results_first_posted>
  <last_update_submitted>December 5, 2017</last_update_submitted>
  <last_update_submitted_qc>December 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Juan J Badimon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Antiplatelet</keyword>
  <keyword>Ticagrelor</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tica-Clop</title>
          <description>Participants received Ticagrelor plus ASA (loading-dose plus daily-dose for 5-7 days), followed by Washout (14 days), and then Clopidogrel plus ASA (loading-dose plus daily-dose for 5-7 days).</description>
        </group>
        <group group_id="P2">
          <title>Clop-Tica</title>
          <description>Participants received Clopidogrel plus ASA (loading-dose plus daily-dose for 5-7 days), followed by Washout (14 days), and then Ticagrelor plus ASA (loading-dose plus daily-dose for 5-7 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Days 1-7</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Days 8-21</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Days 22-28</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Type 2 Diabetic Patients</title>
          <description>All participants receive both Ticagrelor and Clopidogrel (each with aspirin) in a cross-over design. Treatment sequence (Tica-Clop OR Clop-Tica) was randomly assigned and with a 2-week washout period in between (i.e., &quot;Tica/Clop (5-7 days)&quot;, &quot;Washout (14 days)&quot;, and &quot;Clop/Tica (5-7 days)&quot;).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.2" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.9" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes, type-2</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypertension</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypercholesterolemia</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Thrombus Formation</title>
        <description>Thrombus formation in Badimon Perfusion Chamber high-shear) (ex vivo model of thrombosis).</description>
        <time_frame>up to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + Aspirin</title>
            <description>Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + Aspirin</title>
            <description>Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Thrombus Formation</title>
          <description>Thrombus formation in Badimon Perfusion Chamber high-shear) (ex vivo model of thrombosis).</description>
          <units>percentage of baseline size</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hour post loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" spread="8.0"/>
                    <measurement group_id="O2" value="84.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.9" spread="8.0"/>
                    <measurement group_id="O2" value="79.8" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-7 days of maintenance dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" spread="8.3"/>
                    <measurement group_id="O2" value="82.6" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity</title>
        <description>Platelet reactivity by Multiplate Analyzer</description>
        <time_frame>up to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + Aspirin</title>
            <description>Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + Aspirin</title>
            <description>Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity</title>
          <description>Platelet reactivity by Multiplate Analyzer</description>
          <units>percentage of baseline Unit</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hour post-loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="7.4"/>
                    <measurement group_id="O2" value="54.5" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour post-loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="7.5"/>
                    <measurement group_id="O2" value="43.6" spread="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-7 days of maintenance dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="7.7"/>
                    <measurement group_id="O2" value="45.5" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>P2Y12 Reaction Unit (PRU)</title>
        <description>Platelet reactivity by measuring P2Y12 Reaction Unit using Accumetrics VerifyNow</description>
        <time_frame>up to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + Aspirin</title>
            <description>Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + Aspirin</title>
            <description>Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).</description>
          </group>
        </group_list>
        <measure>
          <title>P2Y12 Reaction Unit (PRU)</title>
          <description>Platelet reactivity by measuring P2Y12 Reaction Unit using Accumetrics VerifyNow</description>
          <units>percentage of baseline PRU</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hour post-loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8" spread="7.2"/>
                    <measurement group_id="O2" value="77.8" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour post-loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="7.5"/>
                    <measurement group_id="O2" value="66.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-7 days of maintenance dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.5" spread="7.5"/>
                    <measurement group_id="O2" value="62.7" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Index (PRI)</title>
        <description>Platelet reactivity index by Vasodilator-Stimulated Phosphoprotein phosphorylation (VASP) assay.</description>
        <time_frame>up to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor + Aspirin</title>
            <description>Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).</description>
          </group>
          <group group_id="O2">
            <title>Clopidogrel + Aspirin</title>
            <description>Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity Index (PRI)</title>
          <description>Platelet reactivity index by Vasodilator-Stimulated Phosphoprotein phosphorylation (VASP) assay.</description>
          <units>percentage of baseline PRI</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hour post-loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="2.5"/>
                    <measurement group_id="O2" value="85.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hour post-loading dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="2.5"/>
                    <measurement group_id="O2" value="82.5" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5-7 days of maintenance dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="2.5"/>
                    <measurement group_id="O2" value="68.4" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>there were no adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor + Aspirin</title>
          <description>Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).</description>
        </group>
        <group group_id="E2">
          <title>Clopidrogel + Aspirin</title>
          <description>Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Juan Badimon</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-241-8484</phone>
      <email>juan.badimon@mssm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

